ライフサイエンスコーパス: tumor recurrence

1 ironment contributing to drug resistance and tumor recurrence.

2 d increased overall, locoregional, and mixed tumor recurrence.

3 t vs none; P = .05) were associated with HCC tumor recurrence.

4 roportionately to therapeutic resistance and tumor recurrence.

5 om a surgical approach and suffer from early tumor recurrence.

6 association of race and genetic traits with tumor recurrence.

7 s, which was associated with increased local tumor recurrence.

8 and significance of the racial disparity in tumor recurrence.

9 es effective treatment and virtually assures tumor recurrence.

10 h virus infection, tumor size, cirrhosis and tumor recurrence.

11 functions and a low rate of reoperation for tumor recurrence.

12 mor propagation, therapeutic resistance, and tumor recurrence.

13 tered gene expression may be associated with tumor recurrence.

14 sociated with a significant 25% reduction in tumor recurrence.

15 effect on stem cells that may contribute to tumor recurrence.

16 s a microenvironment that fosters aggressive tumor recurrence.

17 apeutics with anti-inflammatories may reduce tumor recurrence.

18 tumor regression and successfully prevented tumor recurrence.

19 Ipsilateral breast tumor recurrence.

20 ility, enhanced tumor resection, and reduced tumor recurrence.

21 ciated with clinical disease progression and tumor recurrence.

22 er therapeutics to CD133+ cells for reducing tumor recurrence.

23 the effect of the mutations on survival and tumor recurrence.

24 ndent state, delaying or completely blocking tumor recurrence.

25 ffects from radiation, metastasis, and local tumor recurrence.

26 but many treated patients relapse with local tumor recurrence.

27 gression of advanced disease was followed by tumor recurrence.

28 onse and cell cycle gene expression in colon tumor recurrence.

29 ls may resist tumor therapy, and it predicts tumor recurrence.

30 We want to assess if a rising NAS predicts tumor recurrence.

31 ents with ovarian cancer are at high risk of tumor recurrence.

32 nic effects are rarely sufficient to prevent tumor recurrence.

33 c target with reduced risk of resistance and tumor recurrence.

34 ty, higher radiation dose to tumor apex, and tumor recurrence.

35 ) cells are the cause of drug resistance and tumor recurrence.

36 ide clinically useful predictions of time to tumor recurrence.

37 le duct strictures, incomplete ablation, and tumor recurrence.

38 pediatric cancer mortality, primarily due to tumor recurrence.

39 itiating cells (CICs) play a crucial role in tumor recurrence.

40 stem-like cells are thought to contribute to tumor recurrence.

41 oves ITT-OS, and it is not a risk factor for tumor recurrence.

42 that higher LIF levels correlated with local tumor recurrence.

43 sociated with a significantly higher rate of tumor recurrence.

44 aneous treatment more effectively suppressed tumor recurrence.

45 s experienced graft infection, rejection, or tumor recurrence.

46 r cancer resistance to current therapies and tumor recurrence.

47 lete resection, or as salvage treatment upon tumor recurrence.

48 ssociated with higher rates of infection and tumor recurrence.

49 ects, whereas radioresistance contributes to tumor recurrence.

50 ccurate readout of a cell's ability to cause tumor recurrence.

51 its are transient and invariably followed by tumor recurrence.

52 atient survival and increased probability of tumor recurrence.

53 TMZ treatment could inhibit repopulation and tumor recurrence.

54 ts is a promising approach to decrease brain tumor recurrence.

55 ition to gemcitabine chemotherapy to prevent tumor recurrence.

56 (MR) imaging was used to evaluate for local tumor recurrence.

57 city required for metastatic progression and tumor recurrence.

58 ammary cell population expansion, attenuated tumor recurrence.

59 ere used to quantify associations with local tumor recurrence.

60 ion of patients in relation to their risk of tumor recurrence.

61 without any histologic or clinical signs of tumor recurrence.

62 ho showed complete resolution, 4 experienced tumor recurrence.

63 ow-up (67 and 47 months) revealed no sign of tumor recurrence.

64 in 5 years of surgery, and 235 (39%) died of tumor recurrence.

65 sion and inability to adequately monitor for tumor recurrence.

66 been correlated to increased metastasis and tumor recurrence.

67 ape of tumor cells that survive and initiate tumor recurrence.

68 r growth, contribute to resistance and drive tumor recurrence.

69 h single treatment (38% vs 95%; P < .01) and tumor recurrence (15% vs 1%; P = .05).

70 atients with isolated ipsilateral chest wall tumor recurrences (2 of 67; crude rate, 3%).

71 All histopathologically confirmed tumor recurrences (3 of 55 orbits, 5.5%) were correctly

72 gorized in 4 groups: PET/CT for diagnosis of tumor recurrence (303/1,659, 18.3%), PET/CT before start

73 9 months, standard deviation = 55), 16 local tumor recurrences (5.1%) were detected.

74 3.9%), PET/CT to assess therapy response for tumor recurrence (507/1,659, 30.6%), and follow-up PET/C

75 , 18.3%), PET/CT before starting therapy for tumor recurrence (64/1,659, 3.9%), PET/CT to assess ther

76 -up PET/CT after completion of treatment for tumor recurrence (785/1,659, 47.3%).

77 ctive in reducing tumor burden or preventing tumor recurrence after androgen ablation therapy.

78 The prevention of tumor recurrence after curative treatment of hepatocellu

79 ore may be a useful tool to evaluate orbital tumor recurrence after enucleation in children with reti

80 Sixty-three patients (57%) had tumor recurrence after initial resection, and in 30 pati

81 p explain the phenomenon of aggressive local tumor recurrence after liver surgery and offer a potenti

82 Results The rate of tumor recurrence after liver transplantation was 11.5% (

83 vessel invasion of HCC cells, higher risk of tumor recurrence after liver transplantation, strong pho

84 o tumor biology and has predictive value for tumor recurrence after liver transplantation.

85 r-cell renal-cell carcinoma at high risk for tumor recurrence after nephrectomy, the median duration

86 gional renal-cell carcinoma at high risk for tumor recurrence after nephrectomy.

87 llar sclerectomy (13% vs. 8%; P = 0.29), and tumor recurrence after primary treatment (30% vs. 20%; P

88 high-risk tumor features and higher rates of tumor recurrence after primary TTT of (small) choroidal

89 evaluated biometrics for prediction of local tumor recurrence after renal cell carcinoma ablation.

90 However, tumor recurrence after resection, the mechanisms of whic

91 immunity can effectively reduce the risk of tumor recurrence after surgery, facilitating long-term r

92 to develop and validate a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score for pa

93 a novel prognostic index, Risk Estimation of Tumor Recurrence After Transplant (RETREAT), which incor

94 lastoma, antigen escape variants can lead to tumor recurrence after treatment with CAR T cells that a

95 To compare tumor recurrence after treatments, we conducted a prospe

96 extraocular tumor extension was intraocular tumor recurrence after TTT treated with additional TTT (

97 In summary, our work shows how tumor recurrences after long-term latency evolve toward

98 went enucleation because of a presumed local tumor recurrence and 4 additional patients underwent enu

99 -up of 63.8 months, 154 (57.5%) patients had tumor recurrence and 84 (31.3%) were deceased.

100 ha-Fetoprotein (AFP) independently predicted tumor recurrence and correlated with vascular invasion a

101 or size, and number was highly predictive of tumor recurrence and death.

102 ociated with low rates of ipsilateral breast tumor recurrence and has the potential to decrease re-ex

103 ons with oxaliplatin-has reduced the risk of tumor recurrence and improved survival for patients with

104 supported chemotherapy and suppressed local tumor recurrence and improved survival involving both NK

105 reast cancer significantly reduces in-breast tumor recurrence and improves overall survival.

106 ells play a major role in protection against tumor recurrence and infection after allogeneic hematopo

107 toward type 2 immunity, may predict bladder tumor recurrence and influence the mortality of patients

108 Conclusion LRT significantly decreased tumor recurrence and lengthened overall survival.

109 were completed to evaluate risk factors for tumor recurrence and melanoma-related mortality.

110 Tumor recurrence and metastases are the major obstacles

111 the prognosis remains dismal due to frequent tumor recurrence and metastasis after surgery.

112 anticancer therapies, which may account for tumor recurrence and metastasis by regenerating new tumo

113 entified miR-139-5p as a novel biomarker for tumor recurrence and metastasis in CRC.

114 survival of residual cancer cells to foster tumor recurrence and metastasis.

115 tem cells (BCSCs), which are responsible for tumor recurrence and metastasis.

116 in breast cancer tissues are associated with tumor recurrence and metastasis.

117 iVI) is a major risk factor in postoperative tumor recurrence and mortality in hepatocellular carcino

118 lished reporting markedly increased rates of tumor recurrence and occurrence after viral clearance wi

119 HCC metastasis, which is the major cause of tumor recurrence and organ failure.

120 otherapy MRI scan are prognostic for time to tumor recurrence and overall patient survival.

121 y an important role in assessing the risk of tumor recurrence and overall survival.

122 brain parenchyma, which invariably leads to tumor recurrence and patient death.

123 is known to be an important risk factor for tumor recurrence and patient mortality.

124 single-institution series have demonstrated tumor recurrence and patient survival rates that approxi

125 s strongly correlated with decreased time to tumor recurrence and poor patient survival.

126 Importantly, the increased tumor recurrence and progression in human patients with

127 ells that are proposed to be responsible for tumor recurrence and relapse.

128 sed late in progression and often experience tumor recurrence and relapses due to drug resistance.

129 f glioma stem cells, the cells implicated in tumor recurrence and resistance to therapy in patients w

130 Current modalities to predict tumor recurrence and survival in EC are insufficient.

131 ow report that Par-4 is downregulated during tumor recurrence and that Par-4 downregulation is necess

132 ession, with implications for how to prevent tumor recurrence and the establishment of metastatic les

133 metastatic lesions and rationalizations for tumor recurrence and therapeutic failures.

134 nce and is associated with increased risk of tumor recurrence and worse prognosis.

135 t after transurethral resection of a bladder tumor, recurrences and progression remain a problem.

136 32.34 months; none of the patients presented tumor recurrence, and all had correct renal function.

137 ge to assess complete ablation, intrahepatic tumor recurrence, and complications.

138 block copolymer on the therapeutic efficacy, tumor recurrence, and development of drug resistance was

139 s of visual acuity retention, eye retention, tumor recurrence, and melanoma-related mortality were ca

140 lete tumor removal, increases the chances of tumor recurrence, and necessitates costly repeat surgery

141 therapy on posttransplant patient survival, tumor recurrence, and patient survival without transplan

142 r histology or grade, level of suspicion for tumor recurrence, and planned management.

143 levels correlate with increased metastasis, tumor recurrence, and poor outcome.

144 at activation of Notch signaling accelerates tumor recurrence, and that inhibition of Notch signaling

145 Seventeen (77.2%) patients died of tumor recurrence, and the remaining 5 patients died of e

146 ostsurgical contrast enhancement and orbital tumor recurrence, and therefore may be a useful tool to

147 emoradiation, resulting in a typically fatal tumor recurrence approximately 7 mo after diagnosis.

148 ative surgery is followed at a later date by tumor recurrence as a consequence of circulating tumor c

149 (18)F-AH113804 PET detected local tumor recurrence as early as 6 d after surgery in the re

150 mas into groups of high risk and low risk of tumor recurrence as well as short-term and long-term sur

151 Improved tumor recurrence at 2nd and 3rd year may be just due to

152 thout (184 regions) local contrast-enhancing tumor recurrence at follow-up MR imaging (median, 7.3 mo

153 No patient had local tumor recurrence at the 71-month mean follow-up, but of

154 opsy were described in 15.9% (n = 7), but no tumor recurrence at the sclerotomy sites was observed.

155 a Immunoscore provides a potent indicator of tumor recurrence beyond microsatellite-instability stagi

156 Most deaths from breast cancer result from tumor recurrence, but mechanisms underlying tumor relaps

157 ongly associated with therapy resistance and tumor recurrence, but the underlying mechanisms are inco

158 median follow-up of 11 months, there were no tumor recurrences, but 2 new tumors appeared at a remote

159 cape of antigen loss variants and subsequent tumor recurrence by enabling T cells to eliminate cancer

160 wth, improved animal survival, and prevented tumor recurrence by inhibiting cell growth and promoting

161 Ipsilateral breast tumor recurrences classified as TR and NP had clinically

162 th SHH-subgroup MB, in order to decrease the tumor recurrence commonly observed in patients treated w

163 .7%, P = 0.02), with 25.0% exhibiting distal tumor recurrence compared with 2.9% in the Wnt-negative

164 the patients who had an N+ status developed tumor recurrences compared with 5.2% of those who had no

165 hesized to evade current therapies and cause tumor recurrence, contributing to poor patient survival.

166 Tumor recurrence correlated with the number of high-risk

167 last follow-up, and none of 2 patients with tumor recurrence developed metastases in the transplanta

168 Rates of necrosis and tumor recurrence did not differ between groups.

169 t in children with retinoblastoma to exclude tumor recurrence, especially in high-risk patients withi

170 most SCID mice eventually succumbed to local tumor recurrence even with combined cryoablation and CpG

171 d be used first in patients at high risk for tumor recurrence, followed by screening high-risk popula

172 ramide kinase (Cerk) is required for mammary tumor recurrence following HER2/neu pathway inhibition a

173 initiating cells (GICs), which contribute to tumor recurrence following initial response to therapy.

174 search is to develop effective predictors of tumor recurrence following surgery to determine whether

175 ombination of dasatinib and rapamycin delays tumor recurrence following the cessation of treatment.

176 Tumor recurrence following treatment is the major cause

177 Tumor recurrence following treatment remains a major cli

178 dies, failed to confirm significantly better tumor recurrence- free survival at 1 year.

179 ctable early-stage HCCA, excellent long-term tumor recurrence-free patient survival has been achieved

180 on of the tumor is critical to the patient's tumor recurrence-free survival.

181 just as it does in developing organisms, and tumor recurrence frequently manifests from the selective

182 , these results implicate Notch signaling in tumor recurrence from dormant residual tumor cells and p

183 Klatskin tumor patients with a history of tumor recurrence had significantly higher MACC1 expressi

184 cluding resistance to current treatments and tumor recurrence, has been attributed to glioma stemlike

185 ed as a strong independent prognosticator of tumor recurrence (hazard ratio [HR] 4.0, 95% confidence

186 strong, independent, prognostic indicator of tumor recurrence (hazard ratio, 5.063; 95% confidence in

187 emonstrated a significantly reduced risk for tumor recurrence (hazard ratio: 0.65; 95% confidence int

188 additional adjuvant treatments and minimize tumor recurrence; however, there is a delicate balance b

189 tion was associated with a decreased risk of tumor recurrence (HR, 0.41; P = 0.008).

190 otherapy significantly decreased the risk of tumor recurrence (HR, 0.51; P = 0.03).

191 al (HR, 8.336; 2.734-25.418; P < 0.001), and tumor recurrence (HR, 8.031; 3.041-21.206; P < 0.001) th

192 ients at highest risk for ipsilateral breast tumor recurrence (IBTR) after local excision of ductal c

193 e cumulative incidence of ipsilateral breast tumor recurrence (IBTR) as a first event within 10 years

194 Time to ipsilateral breast tumor recurrence (IBTR) as first event.

195 lysis of margin width and ipsilateral breast tumor recurrence (IBTR) from a systematic review of 20 s

196 lysis of margin width and ipsilateral breast tumor recurrence (IBTR) from a systematic review of 33 s

197 To compare ipsilateral breast tumor recurrence (IBTR) in women with DCIS treated with

198 Prognostic factors of ipsilateral breast tumor recurrence (IBTR) may change over time following b

199 The primary outcome was ipsilateral breast tumor recurrence (IBTR).

200 %) showed pathologic findings indicative for tumor recurrence in (68)Ga-PSMA ligand PET/CT.

201 Indications for secondary enucleation were tumor recurrence in 60 (61%), neovascular glaucoma in 21

202 tumors to HER2-targeted therapies and delay tumor recurrence in a transgenic model of HER2-positive

203 and ROS as therapeutic targets for reducing tumor recurrence in breast cancer patients.

204 rminant in apoptosis evasion, which leads to tumor recurrence in breast cancer.

205 acy of high-resolution MRI to detect orbital tumor recurrence in children with retinoblastoma in a la

206 nation of PF-562271 and cabozantinib delayed tumor recurrence in contrast to cabozantinib treatment a

207 Tumor recurrence in glioblastoma (GBM) is, in part, attr

208 NEPTRs) at baseline is associated with later tumor recurrence in glioblastoma.

209 D7, contributing to hepatocarcinogenesis and tumor recurrence in HCC.

210 ER-2 DNA vaccine, prevented HER-2(+) primary tumor recurrence in immunocompetent mice.

211 ic inhibition of TLR9, but not TLR4, delayed tumor recurrence in mouse models of B16 melanoma, MB49 b

212 tion and is spontaneously upregulated during tumor recurrence in multiple genetically engineered mous

213 sociation of lower expression of HEXIM1 with tumor recurrence in patients who received tamoxifen.

214 her tumor biometrics for prediction of local tumor recurrence in patients with renal cell carcinoma a

215 Tumor recurrence in prostate cancer has been attributed

216 The diagnosis of tumor recurrence in rhabdomyosarcoma is extremely challe

217 Kaplan-Meier estimates for tumor recurrence in the 1995 to 2000 group were 29% at 5

218 s and 42% at 10 years, whereas estimates for tumor recurrence in the 2001-2012 group were 11% at 5 ye

219 Conclusion Local tumor recurrence in the NEPTR may be predicted by FA met

220 s an independent predictor for mortality and tumor recurrence in the propensity model (hazard ratio,

221 ciated independently with survival times and tumor recurrence in the test and validation sets.

222 the frequency of CT scans with the hazard of tumor recurrence in time.

223 identified patients at high or low risk for tumor recurrence in two independent patient cohorts.

224 Furthermore, local tumor recurrence increased the risk of metastasis by a h

225 priately timed, highly targeted treatment of tumor recurrence irrespective of tumor type or frontline

226 Tumor recurrence is a leading cause of cancer mortality.

227 Tumor recurrence is a major issue for patients with hepa

228 Orbital tumor recurrence is a rare but serious complication in c

229 y for localized, primary GIST, postoperative tumor recurrence is common.

230 Prediction of tumor recurrence is improved significantly by a model th

231 treatment regimens centered on radiotherapy, tumor recurrence is inevitable and is thought to be driv

232 Tumor recurrence is the leading cause of breast cancer-r

233 in low-grade gliomas (LGGs), but its role in tumor recurrence is unclear.

234 lantation was considered upon development of tumor recurrence/liver function impairment.

235 the long-term, 7 (16.7%) patients had local tumor recurrence (managed with repeat NSS in 6 and compl

236 erved after VEGF neutralization, followed by tumor recurrence mediated by rebound angiogenesis.

237 umor microenvironment, thereby driving early tumor recurrence, metastasis, and poor clinical outcome

238 ression levels are associated with increased tumor recurrence, metastatic foci, and reduced disease-f

239 13 months follow-up, there was intraretinal tumor recurrence (n = 1), subretinal seed recurrence (n

240 ty in 9%, enucleation in 13% (for reasons of tumor recurrence [n = 3] and severe glaucoma [n = 1]), a

241 condary enucleations for uveal melanoma were tumor recurrence, neovascular glaucoma, and tumor nonres

242 ly account for some of the local and distant tumor recurrence observed after treatment.

243 Tumor recurrence occurs in almost 10% after liver transp

244 Although tumor recurrence on AI therapy occurs, the mechanisms un

245 ts who presented with a lesion suggestive of tumor recurrence on conventional MRI 1-6 y (mean, 3 y) a

246 ing was used to evaluate the effect of local tumor recurrence on metastatic rate.

247 resistance, and may serve as reservoirs for tumor recurrence on reoxygenation.

248 ontinuing immunotherapy may result in either tumor recurrence or a durably sustained response.

249 ecipients experienced intraabdominal desmoid tumor recurrence or developed de novo visceral allograft

250 .8 months (range: 6-22 months), there was no tumor recurrence or metastasis.

251 o curative resection subsequently experience tumor recurrence or metastasis.

252 l aberrations, including all 3 patients with tumor recurrence or progression.

253 ients with chromosomal aberrations developed tumor recurrence or progression.

254 diagnosis, and more treatment options after tumor recurrence, outcomes after fluorouracil (FU) -base

255 , which caused significantly higher rates of tumor recurrence (P < .05).

256 y higher MACC1 expression than those without tumor recurrence (P = 0.005).

257 inical outcome than fenestration in terms of tumor recurrence (p = 0.018).

258 ence of orange pigment before TTT (P=0.019), tumor recurrence (P=0.002), and extraocular tumor extens

259 gh GPx2 expression was associated with early tumor recurrence, particularly in the recently identifie

260 s evaluated included surgical complications, tumor recurrence, patient survival, and renal function,

261 esected and mice were given gemcitabine, and tumor recurrence patterns and survival were determined.

262 samples and cell lines associated with early tumor recurrence, poor disease-free survival, and an epi

263 nique, implantation tumor development, local tumor recurrence, presence of metastatic disease after s

264 Adaptive chemoresistance and consequent tumor recurrence present major obstacles to the improvem

265 ecially with I-CCA features, showed a 5-year tumor recurrence rate (10%) and 5-year survival rate (78

266 The overall 5-year tumor recurrence rate (95% confidence interval) was 3.3%

267 The tumor recurrence rate, metastasis occurrence, and surviv

268 to predict clinical outcome, especially the tumor recurrence rate.

269 Tumor recurrence rates at 1, 3, and 5 years were 2.4%, 6

270 Tumor recurrence rates were 25.8% (50 of 194;77.60 recur

271 Tumor recurrence rates were low and mortality rates were

272 However, tumor recurrence remains a concern.

273 Tumor recurrence remains the main reason for breast canc

274 4 cases showed further distant conjunctival tumor recurrence remote from the site of radiotherapy wi

275 Tumor recurrence represents a major clinical challenge.

276 ncer cell plasticity promotes metastasis and tumor recurrence, resulting in patient mortality.

277 A greater understanding of the biology of tumor recurrence should improve adjuvant treatment decis

278 posure to vismodegib is necessary to prevent tumor recurrence, suggesting the existence of a vismodeg

279 patient-detrimental desmoplasia and foretell tumor recurrences, suggesting a useful new prognostic to

280 re significantly lower in regions with later tumor recurrence than in regions without (median FAcontr

281 African Americans had a higher risk of tumor recurrence than whites (hazard ratio, 2.22; 95% CI

282 tory T cells (Tregs) alone failed to reverse tumor recurrence, the combination of PD-L1 blockade with

283 otherapy-induced TGF-beta signaling enhances tumor recurrence through IL-8-dependent expansion of CSC

284 All patients have survived with no tumor recurrence to date at 17-, 27- and 38-month follow

285 microenvironment explains the resistance of tumor recurrences to conventional cancer vaccines despit

286 e analyzed for ITT-OS using a Cox model; and tumor recurrence using 2 competitive risk models.

287 Metastatic disease, overall survival, local tumor recurrence, visual acuity, and secondary enucleati

288 In that local tumor recurrence was associated with a significantly hig

289 The risk of first tumor recurrence was compared between patients not takin

290 Local tumor recurrence was detected in 5 cases (13%) at mean i

291 lar in groups R and T, respectively, whereas tumor recurrence was higher in group R (62% vs 10% in gr

292 f 40 completely ablated tumors, intrahepatic tumor recurrence was observed at 2-18 months.

293 -up MRI exam 32 months after the operation a tumor recurrence was suggested.

294 on characteristic that increased the risk of tumor recurrence was tarsal involvement (AJCC T3 stage l

295 pecificity of MR imaging in the detection of tumor recurrence were 100% (six of six patients) and 52%

296 ultivariate analysis, features predictive of tumor recurrence were presence of symptoms (P<0.001), sh

297 haracteristics significantly associated with tumor recurrence were the presence of positive margins (

298 sively into distant brain tissue, leading to tumor recurrence, which is ultimately incurable.

299 of 115 prostatectomy patients with suspected tumor recurrence who underwent both (11)C-choline PET/CT

300 to-cortex K-ratio most accurately identified tumor recurrence, with highly significant differences bo